Dr. Vikram M. Narayan, MD
Urology (Urology Physician)
- Medicare participating
At a glance
- Medical school
- University of Florida College of Medicine (2013)
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 185
Licensed in Texas since 2017, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Medical school: University of Florida College of Medicine
- 2013Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
GA license 85816 · TX license R4291 (first issued 2017; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Emory University Hospital Atlanta, GA
- Emory University Hospital Midtown Atlanta, GA
- Saint Joseph's Hospital of Atlanta, Inc Atlanta, GA
- Emory Decatur Hospital Decatur, GA
- Grady Memorial Hospital Atlanta, GA
Medical groups
- The Emory Clinic Inc (3,568 clinicians)
- Emory Medical Care Foundation Inc (1,015 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 185
- Services billed
- 5,188
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Bcg live intravesical instillation, 1 mg | 1,291 | 16 |
| Urinalysis, manual test | 74 | 23 |
| Diagnostic exam of bladder and urethra using an endoscope | 71 | 41 |
| Established patient office or other outpatient visit, 30-39 minutes | 49 | 36 |
| Instillation of anti-cancer drug into bladder | 46 | 17 |
| Established patient office or other outpatient visit, 40-54 minutes | 29 | 27 |
| New patient office or other outpatient visit, 60-74 minutes | 20 | 20 |
| Established patient office or other outpatient visit, 20-29 minutes | 15 | 14 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 14 | 14 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | 13 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tamsulosin Hcl Other prescribers in Atlanta, GA | 61 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Atlanta, GA | 34 |
| Tolterodine Tartrate Other prescribers in Atlanta, GA | 19 |
| Oxybutynin Chloride Er (oxybutynin chloride) Other prescribers in Atlanta, GA | 15 |
| Oxybutynin Chloride Other prescribers in Atlanta, GA | 13 |
| Cephalexin Other prescribers in Atlanta, GA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 5 payments worth $5,883 in total to this clinician.
| Ferring Pharmaceuticals Inc. | $4,321 |
|---|---|
| Eli Lilly and Company | $1,562 |
| Compensation for services other than consulting (speaking, faculty) | $4,275 |
|---|---|
| Consulting Fee | $1,400 |
| Food and Beverage | $159 |
| Travel and Lodging | $48.51 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ferring Pharmaceuticals Inc. Nov 6, 2025 | Compensation for services other than consulting (speaking, faculty) ADSTILADRIN · ONCOLOGY | $4,275 |
| Eli Lilly and Company Mar 17, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $1,400 |
| Eli Lilly and Company Mar 6, 2025 | Travel and Lodging travel to SAN FRANCISCO, CA Company’s descriptionTRAVEL EXPENSES RELATED TO PROVIDING RESEARCH RELATED SERVICES | $48.51 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 5 companies. The companies reported $341,127 in research payments for these studies, mostly to the institutions running them.
- A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder
Janssen Research & Development, LLC - A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasiv…
Merck Sharp & Dohme LLC - Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals As · Recruiting · NCT06510374 - A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4)
Janssen Research & Development, LLC - Blue Light Cystoscopy With Cysview Registry
Photocure Inc - A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Ferring Pharmaceuticals As · Recruiting · NCT06545955 - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Ri…
Janssen Research & Development, LLC - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Ri…
Janssen Research & Development, LLC - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Ri…
Janssen Research & Development, LLC - Study name not reported
Organon Llc
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.